Comparing a Minimally Invasive Endoscopic Procedure With Surgery for Early Colon Cancer
Compares endoscopic full-thickness resection with standard surgery in people with early colon cancer.
Plain-language title generated from the registry record
Registry title: Endoscopic Therapy Or Surgery for Early Colon Cancer
Key facts
- Where
- Gdansk, PolandSee the site
- Phase
- Phase 3
Where in Poland
- Medical University Of GdanskGdansk, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Norwegian Department of Health and Social Affairs
- Trial code
- NCT06940947
- Record updated
- 20 November 2025
- Original description
The trial is a randomized head-to-head comparison of the benefits, harms and burdens of endoscopic full-thickness resection (eFTR), a novel, minimally invasive endoscopic treatment modality, for early colon cancer as compared to standard-of-care surgery.Read full original descriptionShow less
Endoscopic THerapy Or Surgery for Early Colon Cancer (ETHOS)
The trial is a randomized head-to-head comparison of the benefits, harms and burdens of endoscopic full-thickness resection (eFTR), a novel, minimally invasive endoscopic treatment modality, for early colon cancer as compared to standard-of-care surgery.
Inclusion: Newly diagnosed biopsy-confirmed colon cancer (adenocarcinoma) with macroscopic suspicion of submucosal invasion considered removable by EFTR as deemed by the local multidisciplinary team (MDT) at the participating center; Size ≤20 mm in diameter as deemed by the colonoscopist; No presence of histopathological high-risk features in biopsy (high grade tumor growth, budding grade 2 or 3, or lymphovascular invasion); Patient eligible for surgical removal as deemed by the local MDT at the participating center; Endoscopic images or video of the tumor; No sign of disease beyond T2N0M0 on pre-treatment imaging, biopsy sampling, and radiographic and clinical evaluation; No contraindication for any of the two treatment arms; Written informed consent; No prior or synchronous CRC; No other malignancy which is not cured; No more than 10 adenomas or serrated polyps; No genetic cancer syndrome (adenomatous or serrated polyposis syndrome; Lynch or Lynch-like syndrome); No inflammatory bowel disease.